Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer

被引：1
|
作者：
Yamaguchi, Teppei [1 ]
Hida, Toyoaki [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan
来源：
TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷 / 08期
关键词：
PHASE-III; MAINTENANCE BEVACIZUMAB; CHEMOTHERAPY; COMBINATION; NIVOLUMAB; DOCETAXEL; EFFICACY; THERAPY; SAFETY;
D O I：
10.21037/tcr.2019.12.57
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E11 / E14
页数：4
相关论文
共 50 条
  • [1] Bevacizumab Plus Carboplatin Plus Nab-paclitaxel for Non-squamous Non-small Cell Lung Cancer in a Real-world Setting
    Tamiya, Akihiro
    Tamiya, Motohiro
    Inagaki, Yuji
    Taniguchi, Yoshihiko
    Nakao, Keiko
    Matsuda, Yoshinobu
    Kawamura, Takahisa
    Kunimasa, Kei
    Inoue, Takako
    Nishino, Kazumi
    Okishio, Kyoichi
    ANTICANCER RESEARCH, 2023, 43 (03) : 1325 - 1330
  • [2] A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL)
    Nogami, Naoyuki
    Kubo, Toshio
    Bessho, Akihiro
    Sakugawa, Makoto
    Ikeo, Satoshi
    Yokoyama, Toshihide
    Seki, Nobuhiko
    Ochiai, Ryosuke
    Fujimoto, Nobukazu
    Murakami, Shuji
    Kaira, Kyoichi
    Harada, Toshiyuki
    Kishino, Daizo
    Takiguchi, Yuichi
    Shimokawa, Tsuneo
    Kiura, Katsuyuki
    Yamashita, Natsumi
    Okamoto, Hiroaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (07) : 805 - 812
  • [3] Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatments for Chinese, treatment-naive, stage IV, non-squamous, non-small-cell lung cancer patients: A retrospective analysis
    Chen, Yingkai
    Kang, Shizhou
    Yan, Ming
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2022, 10 (03):
  • [4] First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN study
    Dechow, Tobias
    Riera-Knorrenschild, Jorge
    Hackanson, Bjorn
    Janssen, Jan
    Schulz, Holger
    Oppermann, Ursula
    Chiabudini, Marco
    von Weikersthal, Ludwig Fischer
    Budweiser, Stephan
    Nacke, Axel
    Taeuscher, Dagmar
    Welslau, Manfred
    Potthoff, Karin
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (01) : 141 - 152
  • [5] First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study
    Dechow, Tobias
    Riera-Knorrenschild, Jorge
    Hackanson, Bjoern
    Janssen, Jan
    Schulz, Holger
    Chiabudini, Marco
    Fischer von Weikersthal, Ludwig
    Budweiser, Stephan
    Nacke, Axel
    Taeuscher, Dagmar
    Welslau, Manfred
    Potthoff, Karin
    CANCER MEDICINE, 2021, 10 (22): : 8127 - 8137
  • [6] Cost-Effectiveness Analysis of Serplulimab Combined with Nab-Paclitaxel Plus Carboplatin Compared to Nab-Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer in China
    Yao, Hongting
    Xu, Kai
    Yu, Man
    Wang, Xiaoye
    Lu, Yingzhi
    Li, Xin
    Wu, Hong
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2025, 18
  • [7] Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies
    Okamoto, Isamu
    Schuette, Wolfgang H. W.
    Stinchcombe, Thomas E.
    Rodrigues-Pereira, Jose
    San Antonio, Belan
    Chen, Jian
    Liu, Jingyi
    John, William J.
    Zinner, Ralph G.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (05) : 937 - 941
  • [8] Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
    Ikeuchi, Nobumitsu
    Igata, Fumiyasu
    Kinoshita, Eriko
    Kawabata, Toshiaki
    Tan, Ibun
    Osaki, Yusuke
    Otsuka, Rikako
    On, Rintaro
    Ikeda, Takato
    Nakao, Akira
    Sasaki, Tomoya
    Aoyama, Takashi
    Hirano, Ryosuke
    Harada, Taishi
    Ebi, Noriyuki
    Fujita, Masaki
    Inoue, Hiroyuki
    ANTICANCER RESEARCH, 2023, 43 (02) : 713 - 724
  • [9] Bevacizumab plus Weekly Paclitaxel with or Without Carboplatin for Previously-treated Non-squamous Non-Small Cell Lung Cancer
    Hata, Akito
    Katakami, Nobuyuki
    Tanaka, Kosuke
    Takeshita, Jumpei
    Matsumoto, Takeshi
    Monden, Kazuya
    Nagata, Kazuma
    Masago, Katsuhiro
    Kaji, Reiko
    Fujita, Shiro
    Tachikawa, Ryo
    Otsuka, Kyoko
    Otsuka, Kojiro
    Tomii, Keisuke
    ANTICANCER RESEARCH, 2014, 34 (1A) : 275 - 281
  • [10] Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer
    Chen, Yi
    Li, Jinyu
    Chen, Shixue
    Zhang, Yibao
    Hu, Yi
    Zhang, Guoqing
    Yan, Xiang
    Jiao, Shunchang
    SCIENTIFIC REPORTS, 2017, 7
12345